About 37 employees are affected, about 13% of its workforce, according to Ocular Therapeutix, Inc's latest layoff filing, on June 3, 2024. As of November 15, 2026, Ocular Therapeutix, Inc has reported this one exit or restructuring plan to the SEC on Form 8-K under Item 2.05. No WARN notice under its name is on file in the states covered here (Form 8-K, June 3, 2024).
10 companies announced layoffs this week, 1 had other signals.
Companies cutting jobs this week. Before you unlock: the company, the number of employees and what is inside. After: every way we found to reach the company. No individual is named in a layoff.
| UPWORK, INC | announced layoffs | |
| PVH CORP. /DE/ | announced layoffs | |
| Battelle | filed a layoff notice for 15 employees | |
| TidalHealth Primary Care | filed a layoff notice for 5 employees | |
| Phunware, Inc. | announced layoffs |
Is this your company?
Owed money by them or selling to them? See the free Snapshot of Ocular Therapeutix, Inc.
Free to see. No signup.
People from Ocular Therapeutix, Inc who say they are open to work
Only people who added themselves are listed here. Nobody is named because of a company announcement or a news story, and we have not checked what anyone says about themselves.
Loading the list…
Affected by the Ocular Therapeutix, Inc layoff? Add yourself to the open-to-work list, free
Your entry
Ocular Therapeutix, Inc reported 1 exit or restructuring plan on Form 8-K under Item 2.05, 1 of 1 stating how many employees or positions are affected. Each fact below is the filing's own sentence, quoted and linked. No WARN notice under this company's name is on file in the states covered here.
Did Ocular Therapeutix have layoffs in 2024? What its filings say
Ocular Therapeutix, Inc (CIK 1393434) reported 1 exit or restructuring plan to the SEC on Form 8-K under Item 2.05. The sentences below are quoted from the filings as written.
Form 8-K filed 2024-06-03
Employees affected
On May 29, 2024, the board of directors (the "Board") of Ocular Therapeutix, Inc. (the "Company") approved a strategic reduction in force to eliminate 37 full-time employees of the Company, primarily in research and development and technical operations and representing approximately 13% of the Company's workforce, as part of an initiative to prioritize Company resources on the clinical development of AXPAXLI (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related macular degeneration.
Expected charges
The Company anticipates incurring total restructuring costs of approximately $1.0 to $2.0 million, which includes garden leave, severance benefits and related costs and which are expected to result in cash expenditures during the second and third quarters of 2024.
Timing
The Company currently expects to substantially complete the reduction in force and to record the related restructuring charges in the second quarter of 2024.
Also on the record for Ocular Therapeutix, Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 9, 2026 | Leadership change: Riad Sherif appointed, Director, and 1 more | — | Leadership changes | Source |
| October 16, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7% of the class | 5%+ stakes | Source |
| June 12, 2026 | Leadership change: Jason Robins appointed, Chief Financial Officer | — | Leadership changes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 9.53% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | 3.2% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G, by Deep Track Capital, LP | 5.13% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 4.31% of the class | 5%+ stakes | Source |
| January 23, 2026 | Leadership change: Jason Robins appointed, Chief Financial Officer, and 1 more | — | Leadership changes | Source |
| December 8, 2025 | Stake report, Schedule 13G, by SUMMER ROAD LLC | 5.7% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 6.18% of the class | 5%+ stakes | Source |
Keep reading
More on Ocular Therapeutix, Inc and the records around it.
Ocular Therapeutix, Inc elsewhere on the record
- 5%+ stake filings Jul 2026
- Leadership changes Jun 2026
- Who owns it
Companies that share a holder
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Lycia Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- Deep Track Capital, LP also filed stake reports on 60 other companies: Mentari Therapeutics, Inc. (Nov 2026), Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026)
- FMR LLC also filed stake reports on 762 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Ocular Therapeutix, Inc
Get an email when Ocular Therapeutix, Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Ocular Therapeutix, Inc?
Want the whole picture on Ocular Therapeutix, Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Ocular Therapeutix, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ocular Therapeutix, Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 16 records.
Tools for this story
Each opens in a new tab, filled in for Ocular Therapeutix, Inc. With no account yet, you sign up free and land on the result.
Public companies must also report to the SEC, on Form 8-K under Item 2.05, when they commit to an exit or restructuring plan that will cost them material charges, which is how most large layoffs and closures by listed companies are disclosed. Those filings are national, so they cover companies in every state. Each sentence shown from one is quoted exactly and linked to the filing; where a filing does not state a figure, none is shown.
Where this comes from
Employers covered by the federal WARN Act, and by the stricter laws some states add, must give written notice before a mass layoff or a site closure. The state labor department publishes those notices. Every row here is one of them, taken from that state's own published file and linked to it, so each figure can be checked at the source.
A notice states the employer, the location, the number of employees affected, and when the layoff or closure takes effect. It does not state a reason, and neither does this page. Where a company also appears in SEC filings under the same name and in the same state, its recorded fundraising is shown alongside, as a matter of record rather than as an explanation. New Jersey and Pennsylvania list a notice under the month it was posted or received, not the day, so their notices show a month. Tennessee gives the county rather than the city.
Who owns Ocular Therapeutix, Inc.? Owners, funding and legal record
Cite this page
https://mentionfox.com/layoffs/ocular-therapeutix